# MK-3475/BCG in High Risk Superficial Bladder Cancer

> **NCT02324582** · PHASE1 · COMPLETED · sponsor: **Southern Illinois University** · enrollment: 18 (actual)

## Conditions studied

- Bladder Cancer

## Interventions

- **DRUG:** Intravenous MK-3475/ Intravesical BCG

## Key facts

- **NCT ID:** NCT02324582
- **Lead sponsor:** Southern Illinois University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-06
- **Primary completion:** 2021-11-18
- **Final completion:** 2023-03-27
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2024-09-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02324582

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02324582, "MK-3475/BCG in High Risk Superficial Bladder Cancer". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT02324582. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*